protocolSection identificationModule nctId: NCT06319846, orgStudyIdInfo id: ZLRK202312, briefTitle: Tirofiban for Patients With intraCranial Artery Stenosis and High-risk Acute Non-disabling Cerebrovascular Events(CHANCE-4）, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-03, primaryCompletionDateStruct date: 2025-06, completionDateStruct date: 2026-06, studyFirstPostDateStruct date: 2024-03-20, lastUpdatePostDateStruct date: 2024-03-20, sponsorCollaboratorsModule leadSponsor name: Beijing Tiantan Hospital, class: OTHER, descriptionModule briefSummary: The CHANCE-4 study is a multicenter, double-blind, double-simulation, randomized controlled study. In patients at high-risk for mild ischemic stroke or transient ischemic attack with symptomatic intracranial artery stenosis within 24 hours of onset, we will examine whether treatment with tirofiban for 48 hours reduce the risk of ischemic stroke recurrence within 90 days compared with placebo., conditionsModule conditions: Ischemic Stroke, Acute, conditions: TIA, conditions: Symptomatic Intracranial Artery Stenosis, designModule studyType: INTERVENTIONAL, phases: PHASE3, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: PREVENTION, maskingInfo masking: QUADRUPLE, whoMasked: PARTICIPANT, whoMasked: CARE_PROVIDER, whoMasked: INVESTIGATOR, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 4674, type: ESTIMATED, armsInterventionsModule interventions name: Tirofiban, interventions name: Tirofiban placebo, outcomesModule primaryOutcomes measure: New ischemic stroke, primaryOutcomes measure: BARC type 3 or type 5 bleeding, secondaryOutcomes measure: New ischemic stroke, secondaryOutcomes measure: Any new vascular events, secondaryOutcomes measure: Proportion of patients with disabling stroke, secondaryOutcomes measure: Occurrence and severity of stroke or transient ischemic attack, secondaryOutcomes measure: Proportion of patients with aggravated neurological impairment, otherOutcomes measure: BARC type 3 or type 5 bleeding, otherOutcomes measure: All bleeding events, otherOutcomes measure: Death, otherOutcomes measure: Adverse events or serious adverse events, otherOutcomes measure: BARC type 2 or type 3 or 5 bleeding, eligibilityModule sex: ALL, minimumAge: 40 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: The 2nd Affiliated Hospital of Harbin Medical University, city: Harbin, state: Heilongjiang, zip: 150086, country: China, contacts name: Lihua Wang, role: CONTACT, phone: 13100881600, email: wanglh211@163.com, geoPoint lat: 45.75, lon: 126.65, locations facility: People's Hospital of Qihe County, city: Dezhou, state: Shandong, zip: 251199, country: China, contacts name: Haitao Li, role: CONTACT, phone: 13869215737, email: userfiled@126.com, geoPoint lat: 37.45127, lon: 116.31046, locations facility: Liaocheng People's Hospital（Liaocheng Brain Hospital）, city: Liaocheng, state: Shandong, zip: 252001, country: China, contacts name: Xiafeng Yang, role: CONTACT, phone: 13326356005, email: Cranialnerves@163.com, geoPoint lat: 36.45596, lon: 115.97766, locations facility: Third People's Hospital of Liaocheng, city: Liaocheng, state: Shandong, zip: 252004, country: China, contacts name: Liguo Chang, role: CONTACT, phone: 17763559299, email: chliguo@163.com, geoPoint lat: 36.45596, lon: 115.97766, locations facility: Yantai Penglai traditional Chinese medicine hospital, city: Yantai, state: Shandong, zip: 265699, country: China, geoPoint lat: 37.47649, lon: 121.44081, hasResults: False